Oruka Therapeutics (HQ1) Price & Analysis

0 Followers

HQ1 Stock Chart & Stats

€80.50

€1.00(1.30%)

At close: Jul 30 4:00 PM EDT

€80.50

€1.00(1.30%)

Day’s Range― - ―

52-Week Range€22.20 - €96.50

Previous CloseN/A

Volume34.00

Average Volume (3M)1.00

Market Cap

€4.66B

Enterprise Value€5.12B

Total Cash (Recent Filing)€873.56M

Total Debt (Recent Filing)€2.55M

Price to Earnings (P/E)―

Beta0.22

Next Earnings

Nov 18, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.47

Shares Outstanding66,209,700

10 Day Avg. Volume0

30 Day Avg. Volume1

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.93

Price to Sales (P/S)0.00

P/FCF Ratio-15.64

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€137.56

Price Target Upside70.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-2.14

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Strong Capital BaseExtremely low leverage gives Oruka substantial financial flexibility while it advances its clinical programs. The sharply larger asset base indicates a well-capitalized platform, reducing balance-sheet pressure and supporting continued development investment over the next several quarters.

Experienced Commercial LeadershipHiring a commercial leader with experience across dermatology, immunology, and biologic products strengthens Oruka’s readiness for future commercialization. This adds relevant execution expertise as candidates advance and signals deliberate investment in building capabilities beyond research.

Cash Burn Closely Reflects Operating LossesA close relationship between free cash flow and net loss makes Oruka’s spending profile relatively transparent and suggests losses primarily reflect direct development investment rather than large non-cash adjustments. That clarity can improve financial planning as clinical programs progress.

Bears Say

Pre-revenue Business ModelOruka has no product revenue to offset research and development spending, leaving its financial profile dependent on clinical progress and eventual commercialization. Until revenue or partnering inflows emerge, the company lacks an internally generated funding engine for its operations.

Widening Net And Operating LossesExpanding losses show that development spending is rising faster than any current income contribution, increasing the scale of future funding requirements. This weakens near-term earnings visibility and leaves financial performance highly dependent on successful clinical and commercial execution.

Accelerating Cash BurnThe deterioration in free cash flow indicates that Oruka is consuming capital at an accelerating rate while remaining pre-revenue. Continued burn can shorten the period supported by existing resources and increase dependence on future financing, partnerships, or successful product development.

Oruka Therapeutics News

Oruka Therapeutics ORKA-001 data meet base case, says Clear Street

Clear Street says Oruka Therapeutics (ORKA)’ ORKA-001 update today met its base case. PASI 100 increased to 71.4%...

30d ago

ORKA

Oruka Therapeutics announces Week 28 results for ORKA-001

Oruka Therapeutics (ORKA) announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel...

30d ago

ORKA

ORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for Investors

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is running a...

13d ago

ORKA

ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. The study A Multicenter, Randomized, Double-Blinded,...

28d ago

ORKA

Wedbush biotech analyst holds an analyst/industry conference call

Biotech Analyst Zhong, along with Philip J. Mease, MD, of the University of Washington School of Medicine, discuss...

1M ago

MLTX

ORKA

Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating...

2M ago

ORKA

Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer

Oruka Therapeutics ( ($ORKA) ) has issued an announcement. On July 22, 2026, Oruka Therapeutics appointed veteran commercial...

2M ago

ORKA

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins...

2M ago

ARQT

ORKA

Oruka Therapeutics files $1B mixed securities shelf

16:20 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

ORKA

Oruka Therapeutics: Strong Clinical Momentum and Pipeline Optionality Support Buy Rating and Unchanged $151 Price Target

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a...

2M ago

ORKA

Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)

“The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward...

2M ago

ORKA

Oruka Therapeutics: Buy Rating Reaffirmed as EVERLAST-A Data Support Once-Yearly ORKA-001; $120 Price Target Maintained

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics today and set a price target...

3M ago

ORKA

Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Oruka Therapeutics today and set a price target...

3M ago

ORKA

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts

Healthcare remains one of the market’s most steady sectors this year, backed by biotech innovation and medical device...

4M ago

BSX

INSM

HQ1 FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was €22.20 and its highest was €96.50 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is €4.66B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Aug 10, 2026. The company reported -€0.481 earnings per share for the quarter, missing the consensus estimate of -€0.448 by -€0.033.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics does not currently pay dividends.

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.52.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 66,209,700 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -€0.481 in its last earnings report, missing expectations of -€0.448. Following the earnings report the stock price went up 2.367%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in DE:HQ1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-20.76%

Trailing 12-Months

Asset Growth

218.78%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics (HQ1) Earnings & Revenues

Historic Earnings Reports

HQ1 Stock 12 Month Forecast

Average Price Target

€137.56

▲(70.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"€15","56":"€56","97":"€97","138":"€138","179":"€179"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":178.06997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€178.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.559051825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€137.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.841982,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€106.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,56,97,138,179],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,82.92845923076923,90.85691846153847,98.78537769230769,106.71383692307693,114.64229615384616,122.57075538461538,130.49921461538463,138.42767384615385,146.35613307692307,154.28459230769232,162.21305153846154,170.14151076923076,{"y":178.06997,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,79.81223475576923,84.62446951153846,89.43670426730769,94.24893902307693,99.06117377884615,103.87340853461538,108.68564329038462,113.49787804615386,118.31011280192308,123.12234755769231,127.93458231346155,132.74681706923076,{"y":137.559051825,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,77.44938323076923,79.89876646153846,82.34814969230769,84.79753292307693,87.24691615384616,89.69629938461539,92.14568261538462,94.59506584615384,97.04444907692309,99.49383230769232,101.94321553846154,104.39259876923077,{"y":106.841982,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >